Breaking News
Get 40% Off 0
😲 Missed the +20.8% surge in our stock strategy last month? Not again! Get premium insights Get 40% Off Now
Close

Hikma Pharmaceuticals PLC (HIK)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1,922.50 -28.50    -1.46%
08:00:27 - Real-time Data. Currency in GBP ( Disclaimer )
  • Volume: 44,796
  • Bid/Ask: 1,921.50 / 1,923.00
  • Day's Range: 1,915.00 - 1,939.81
Type:  Equity
Market:  United Kingdom
ISIN:  GB00B0LCW083 
SEDOL:  B0LCW08
Hikma Pharma 1,922.50 -28.50 -1.46%

HIK Balance Sheet

 
Featured here, the Balance Sheet for Hikma Pharmaceuticals PLC, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Current Assets 2100 2100 2176 2176
Cash and Short Term Investments 205 205 294 294
Cash - - - -
Cash & Equivalents 205 205 272 272
Short Term Investments - - - -
Total Receivables, Net 873 873 905 905
Accounts Receivables - Trade, Net 789 789 846 846
Total Inventory 891 891 859 859
Prepaid Expenses - - 85 85
Other Current Assets, Total 131 131 33 33
Total Assets 4680 4680 4619 4619
Property/Plant/Equipment, Total - Net 1141 1141 1087 1087
Property/Plant/Equipment, Total - Gross 2156 2156 - -
Accumulated Depreciation, Total -1015 -1015 - -
Goodwill, Net 388 388 390 390
Intangibles, Net 712 712 694 694
Long Term Investments 10 10 51 51
Note Receivable - Long Term 84 84 59 59
Other Long Term Assets, Total 103 103 21 21
Other Assets, Total 375 375 209 209
Total Current Liabilities 1339 1339 1215 1215
Accounts Payable 568 568 505 505
Payable/Accrued - - - -
Accrued Expenses - - 167 167
Notes Payable/Short Term Debt 46 46 113 113
Current Port. of LT Debt/Capital Leases 115 115 108 108
Other Current liabilities, Total 610 610 322 322
Total Liabilities 2471 2471 2417 2417
Total Long Term Debt 1030 1030 1091 1091
Long Term Debt 975 975 1032 1032
Capital Lease Obligations 55 55 59 59
Deferred Income Tax 25 25 26 26
Minority Interest 11 11 13 13
Other Liabilities, Total 20 20 -697 -41
Total Equity 2209 2209 2202 2202
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 40 40 40 40
Additional Paid-In Capital 282 282 282 282
Retained Earnings (Accumulated Deficit) 2158 2158 2146 2146
Treasury Stock - Common - - - -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total -271 -271 -266 -266
Total Liabilities & Shareholders' Equity 4680 4680 4619 4619
Total Common Shares Outstanding 220.72 220.72 220.99 220.99
Total Preferred Shares Outstanding - - - -
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

HIK Comments

Write your thoughts about Hikma Pharmaceuticals PLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email